Evidence map›Paper›PMID 30022099›Full record

ReviewNature reviews. Endocrinology2018

Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications.

Geert Jan Biessels, Florin Despa

4 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 775 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
775citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04632719 nacompletednot on this mapstarted 2020, after this paper: background citation

MentalPlus® for Assessment and Rehabilitation of Cognitive Functions After Remission of Symptoms of COVID-19

TypeinterventionalSponsorUniversity of Sao PauloRan2020 to 2023Enrolled200ConditionsCognitive Impairment, Covid19, Cognitive Dysfunction, Depression, AnxietyArmsThe use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19
NCT06735651 narecruitingnot on this mapstarted 2024, after this paper: background citation

Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Female Adults With Prediabetes.

TypeinterventionalSponsorGeorgia State UniversityRan2024 to 2026Enrolled30ConditionsPrediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female, Adult, Endothelial Function (Reactive Hyperemia)ArmsWild Blueberry, Placebo
NCT07284316 phase2 / phase3active not recruitingnot on this mapstarted 2025, after this paper: background citation

Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance: A Randomized Clinical Trial

TypeinterventionalSponsorInstituto Mexicano del Seguro SocialRan2025 to 2027Enrolled100ConditionsCognitive Decline, Subjective Cognitive Impairment, Insulin ResistanceArmsTurmeric extract, Control: Placebo. 500mg gelatin in capsules 2 times a day
NCT07731191 narecruitingnot on this mapstarted 2026, after this paper: background citation

Development of Digital Solutions for the Prediction of the Biological Mechanisms of Alzheimer's Disease Through the Analysis of Risk Factors (PrevAI)

TypeinterventionalSponsorIRCCS Centro San Giovanni di Dio FatebenefratelliRan2026 to 2026Enrolled240ConditionsMild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)ArmsDigital solution for the prediction of the biological mechanisms of Alzheimer's disease through the analysis of risk factors
3 · Its place in the literature

Who cites it

775 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Trial
  14. Trial
  15. Trial
  16. Systemic Diseases and the Eye: A Translational Perspective on Diabetes.Chronic diseases and translational medicine · 2026
    Review
  17. Article
  18. Article
  19. Review
  20. Article

715 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Geert Jan BiesselsDepartment of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands. G.J.Biessels@umcutrecht.nl.
Florin DespaDepartment of Pharmacology and Nutritional Sciences and Department of Neurology, University of Kentucky, Lexington, KY, USA.

Funding

University of Kentucky Alzheimer's Disease Core Center - Biomarker CoreP30AG028383 · NIA · UNIVERSITY OF KENTUCKY · PI GOLD, BRIAN TIMOTHY, VAN ELDIK, LINDA J · 2006 to 2020
$23.3M
The Amylin Dyshomeostasis Hypothesis of Vascular Contributions to Cognitive Impairment and Dementia (VCID)R01NS116058 · NINDS · UNIVERSITY OF KENTUCKY · PI DESPA, FLORIN · 2020 to 2024
$3.8M
Programming amylin secretion to slow brain aging - an animal modelR01AG057290 · NIA · UNIVERSITY OF KENTUCKY · PI DESPA, FLORIN, THINAKARAN, GOPAL · 2017 to 2021
$3.3M
Role of Systemic Amylin Dyshomeostasis in Alzheimer's DiseaseR01AG053999 · NIA · UNIVERSITY OF KENTUCKY · PI DESPA, FLORIN · 2016 to 2020
$1.9M
Hyperamylinemia in Diabetic Heart Disease: Mechanisms, Responses, and PreventionR01HL118474 · NHLBI · UNIVERSITY OF KENTUCKY · PI DESPA, FLORIN · 2013 to 2016
$1.5M
NHLBI NIH HHS R01 HL118474NIA NIH HHS P30 AG028383NIA NIH HHS R01 AG053999NIA NIH HHS R01 AG057290NINDS NIH HHS R01 NS116058
6 · The paper itself

Abstract

Cognitive dysfunction is increasingly recognized as an important comorbidity of diabetes mellitus. Different stages of diabetes-associated cognitive dysfunction exist, each with different cognitive features, affected age groups and prognoses and probably with different underlying mechanisms. Relatively subtle, slowly progressive cognitive decrements occur in all age groups. More severe stages, particularly mild cognitive impairment and dementia, with progressive deficits, occur primarily in older individuals (>65 years of age). Patients in the latter group are the most relevant for patient management and are the focus of this Review. Here, we review the evolving insights from studies on risk factors, brain imaging and neuropathology, which provide important clues on mechanisms of both the subtle cognitive decrements and the more severe stages of cognitive dysfunction. In the majority of patients, the cognitive phenotype is probably defined by multiple aetiologies. Although both the risk of clinically diagnosed Alzheimer disease and that of vascular dementia is increased in association with diabetes, the cerebral burden of the prototypical pathologies of Alzheimer disease (such as neurofibrillary tangles and neuritic plaques) is not. A major challenge for researchers is to pinpoint from the spectrum of diabetes-related disease processes those that affect the brain and contribute to development of dementia beyond the pathologies of Alzheimer disease. Observations from experimental models can help to meet that challenge, but this requires further improving the synergy between experimental and clinical scientists. The development of targeted treatment and preventive strategies will therefore depend on these translational efforts.

Indexed as

AgedAge DistributionAlzheimer DiseaseCognitive DysfunctionComorbidityDementiaDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedNeuroimagingPrevalencePrognosisRisk AssessmentSeverity of Illness Index

Identifiers

PMID30022099
PMCPMC6397437

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.